Equillium
Equillium
EQ
NASDAQ
0.74
USD
0.00%
About
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways.
The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling.
The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 248.3K |
| Three Month Average Volume | 7.5M |
| High Low | |
| Fifty-Two Week High | 3.25 USD |
| Fifty-Two Week Low | 0.45 USD |
| Fifty-Two Week High Date | 26 Feb 2024 |
| Fifty-Two Week Low Date | 13 Nov 2023 |
| Price and Volume | |
| Current Price | 1.07 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 46.53% |
| Thirteen Week Relative Price Change | -33.35% |
| Twenty-Six Week Relative Price Change | -61.07% |
| Fifty-Two Week Relative Price Change | 5.42% |
| Year-to-Date Relative Price Change | 24.97% |
| Price Change | |
| One Day Price Change | -0.93% |
| Thirteen Week Price Change | -28.67% |
| Twenty-Six Week Price Change | -57.20% |
| Five Day Price Change | -1.81% |
| Fifty-Two Week Price Change | 32.10% |
| Year-to-Date Price Change | 47.99% |
| Month-to-Date Price Change | 43.20% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.64028 USD |
| Book Value Per Share (Most Recent Quarter) | 0.63326 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.64028 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.63326 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.27017 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.03909 USD |
| Revenue Per Share (Trailing Twelve Months) | 1.20165 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.384 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.23774 USD |
| Normalized (Last Fiscal Year) | -0.384 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.384 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.23727 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.384 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.23774 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.15916 USD |
| Cash Per Share (Most Recent Quarter) | 0.94 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.38037 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.23081 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.44471 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -214 |
| Cash Flow Revenue (Trailing Twelve Months) | -37 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -18.31% |
| Pretax Margin (Last Fiscal Year) | -35.35% |
| Pretax Margin (5 Year) | -327.23% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -40.24% |
| Operating Margin (Trailing Twelve Months) | -22.79% |
| Operating Margin (5 Year) | -329.18% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -36.96% |
| Net Profit Margin (Trailing Twelve Months) | -19.52% |
| Net Profit Margin (5 Year) | -328.35% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -29.73% |
| Tangible Book Value (5 Year) | -19.05% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 51.83% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 26.25% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 7.48% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 113.18% |
| EPS Change (Trailing Twelve Months) | 55.00% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -33,299,000 |
| Net Debt (Last Fiscal Year) | -40,866,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 |
| Price to Sales (Trailing Twelve Months) | 1 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -21,833,000 |
| Free Cash Flow (Trailing Twelve Months) | -15,774,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -20.68% |
| Return on Assets (Trailing Twelve Months) | -16.37% |
| Return on Assets (5 Year) | -46.81% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -48.92% |
| Return on Equity (Trailing Twelve Months) | -33.67% |
| Return on Equity (5 Year) | -67.04% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -38.46% |
| Return on Investment (Trailing Twelve Months) | -29.58% |
| Return on Investment (5 Year) | -57.36% |